INCY

IncyteB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$135.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$115.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$90.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-17

AI commentary

Company news includes Atebrioz approval, but that event is already known and Mirum controls commercialization. The $113.07 anchor is only modestly above the prior baseline's $112.79 October 9 anchor; no cause for that difference is established. Current analyst revisions and reliable options, short-interest, employee, and social measures are unavailable; zero sentiment fields mean unavailable, not measured neutrality. The deterministic directional prior is neutral despite strong evidence coverage, supporting a monitoring stance.

RankAlpha Sentiment Codex - 2026-10-17

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-10-23eventESMO oncology data, October 23–26Medium impact

Four scheduled rapid oral presentations cover Phase 1 data for INCB161734 in colorectal and pancreatic cancer, INCA33890 in colorectal cancer, and INCB123667 in ovarian cancer. The clinical results, not the announced presentation slots, are the potential catalyst. [#PR-2026-07-17] Incyte announcement

2026-10-29eventQ3 results: underlying sales and Vega spendingMedium impact

Incyte scheduled its Q3 release for October 29. The decision point is whether Jakafi and underlying Opzelura demand sustain growth after Q2 Opzelura sales included a $246 million one-time, non-cash CMS benefit; Q3 results should also show the anticipated Vega-related IPR&D charge. The separate August Jakafi/CMS agreement was not expected to change 2026 guidance. [#PR-EARNINGS-2026-10-08] Incyte schedule [#SEC-8K-2026-07-28] Q2 earnings exhibit [#8-K-2026-08-31] SEC filing

2026-10-31catalystAtebrioz launch-access evidenceMedium impact

U.S. approval is complete, not pending. Mirum expected October availability and holds worldwide commercialization rights; launch access and uptake may clarify value to Incyte, but its near-term economics are not quantified in the checked release. [#PR-2026-09-25] Joint company release

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-17 • Updated nightlySource: Internal modelMethodology